Can-Fite BioPharma Ltd. (CANF) Fair Value 2026

CANF · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

DANGER (80/100)

Quick Summary — As of 2026-08-27, Can-Fite BioPharma Ltd. (CANF) trades at $3.37. QOC: 2.5/10. Value Trap Risk: 80/100 (DANGER). 0/13 models active.

Key Facts

Ticker
CANF
Price
$3.37
Quality Score
2.5/10
Value Trap Risk
80/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 80 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give CANF?

0 Intrinsic Value Models vs. Current Price ($3.37)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Can-Fite BioPharma Ltd. (CANF) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Can-Fite BioPharma Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CANF?

0 of 13 models are currently active for CANF. See which stocks rank higher →

How Does CANF Rank in Biotechnology?

Among 620 Biotechnology stocks, CANF ranks #603 by Quality of Company score. CirclFi's QOC score of 2.5/10 evaluates 32 fundamental signals. A score of 2.5 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Can-Fite BioPharma Ltd., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is CANF a Value Trap?

CirclFi's Value Trap algorithm assigns CANF a score of 80/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Can-Fite BioPharma Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Can-Fite BioPharma Ltd. scores 2.5 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones. The elevated Value Trap score, however, warrants additional due diligence.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CANF valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Can-Fite BioPharma Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

GLMDGalmed Pharmaceuticals Ltd.QOC 2.5TLSATiziana Life Sciences LtdQOC 2.5XTLBXTL Biopharmaceuticals Ltd.QOC 2.5EPRXEupraxia Pharmaceuticals Inc.QOC 2.4OKYOOKYO Pharma LimitedQOC 2.5EVAXEvaxion A/SQOC 2.4STTKShattuck Labs, Inc.QOC 6.1IMNMImmunome, Inc.QOC 5.1AZTRAzitra, Inc.QOC 4.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: GLMD · TLSA · XTLB · EPRX · OKYO · EVAX · STTK · IMNM · AZTR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CANF?

6 companies across all industries closest to CANF’s Quality of Company score of 2.5/10.

BANLCBL International LimitedQOC 2.5CLPSCLPS IncorporationQOC 2.5GPGreenPower Motor Company Inc.QOC 2.5HAOHaoxi Health Technology LimitedQOC 2.5ASAmer Sports, Inc.QOC 2.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BANL · CLPS · GP · HAO · AS · NVDA

Where Does CANF Sit in CirclFi's Biotechnology Rankings?

CANF is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Can-Fite BioPharma Ltd.’s Valuation?

What is Can-Fite BioPharma Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Can-Fite BioPharma Ltd. (CANF). The Quality of Company score is 2.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CANF overvalued or undervalued right now?

At $3.37, 0 of 0 active models suggest CANF may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Can-Fite BioPharma Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 2.5 mean for CANF?

Can-Fite BioPharma Ltd.'s QOC of 2.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CANF?

CirclFi analyzes CANF with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CANF a value trap in 2026?

Can-Fite BioPharma Ltd.'s Value Trap score is 80/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Can-Fite BioPharma Ltd. (CANF) a Quality of Company score of 2.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/CANF/ · Methodology
Primary sources for this CANF valuation
  • Financial statements: Can-Fite BioPharma Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001536196) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CANF as of ; valuations recomputed .